ravuconazole Report issue

Small molecule Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Ravuconazole is a potent triazole antifungal, the development of which was discontinued in 2007. The drug has shown to have a similar spectrum of activity to voriconazole, with an increased half-life. However, ravuconazole has limited activity against species of Fusarium, Scedosporium, and Zygomycetes.   Wikipedia

Chemistry

  • SMILES: C[C@@H](c1nc(-c2ccc(C#N)cc2)cs1)[C@](O)(Cn1cncn1)c1ccc(F)cc1F
  • InChIKey: OPAHEYNNJWPQPX-RCDICMHDSA-N
  • Mol. Mass: 437.48
  • ALogP: 4.24
  • ChEMBL Molecule:
    ravuconazole  
More Chemistry

Pharmacology

Alternative names

3-(4-(4-cyanophenyl)thiazol-2-yl)-2-(2,4-difluorophenyl)-1-(1h-1,2,4-triazol-1-yl)-2-butanol | bms-207147 | er 30346 | er-30346 | ravuconazole

Organizations (2)

Research & Development (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (11)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (11)


 

Breast Neoplasms (Phase 1/Phase 2)

Gestational Trophoblastic Disease (Phase 1/Phase 2)

Infections (Phase 1/Phase 2)

Leukemia (Phase 1/Phase 2)

Lymphoma (Phase 1/Phase 2)

Multiple Myeloma (Phase 1/Phase 2)

Myelodysplastic Syndromes (Phase 1/Phase 2)

Myeloproliferative Disorders (Phase 1/Phase 2)

Neuroblastoma (Phase 1/Phase 2)

Ovarian Neoplasms (Phase 1/Phase 2)

Testicular Neoplasms (Phase 1/Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial Organizations: 2

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue